CryoPort (NASDAQ:CYRX) Posts Earnings Results, Misses Expectations By $0.03 EPS

CryoPort (NASDAQ:CYRX - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03), Zacks reports. CryoPort had a net margin of 41.57% and a negative return on equity of 7.84%. The business had revenue of $47.80 million during the quarter, compared to the consensus estimate of $44.86 million.

Here are the key takeaways from CryoPort's conference call:

• Cryoport reported $47.8 million in Q1 revenue, up 16% year‑over‑year, with commercial cell & gene therapy revenue +26% and clinical trial revenue +18%, and raised full‑year 2026 revenue guidance to $192–$196 million.
• Management expects to reach positive adjusted EBITDA in the second half of 2026 and delivered a $2.2 million year‑over‑year improvement in adjusted EBITDA from continuing operations in Q1.
• Cryoport is supporting a record 766 global clinical trials (net +55 YoY), including 91 Phase III trials, and now supports 21 commercial therapies with up to 8 additional potential approvals expected in 2026.
• Operational milestone — IntegriCell shipped its first cryopreserved clinical trial patient materials from Houston and Liège, signalling initial commercial activity for the integrated preservation service.
• Product strength — Life Sciences Products grew 15% driven by strong demand for MVE cryogenic systems and the new Fusion 800 Series, which management says expands addressable markets and supports a high‑single‑digit product growth outlook.

CryoPort Stock Performance

Shares of NASDAQ CYRX opened at $12.19 on Wednesday. CryoPort has a fifty-two week low of $5.31 and a fifty-two week high of $12.65. The stock has a market cap of $611.94 million, a PE ratio of 9.03 and a beta of 1.75. The stock has a fifty day moving average of $8.99 and a 200-day moving average of $9.34.

Trending Headlines about CryoPort

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Q1 revenue beat and healthy growth — Revenue was $47.8M (vs. ~$44.9M est.), up 16% year‑over‑year; Commercial cell & gene therapy (CGT) revenue grew 26% to $9.1M and Life Sciences segments also grew. Press Release
• Positive Sentiment: Company raised FY‑2026 revenue guidance to $192M–$196M, slightly above consensus — management is signaling continued top‑line momentum. Press Release
• Positive Sentiment: Analyst upgrades / price‑target increases — BTIG raised its target to $17 (buy) and Needham raised its target to $15 (buy), providing fresh buy‑side support. The Fly (BTIG) TickerReport (Needham)
• Neutral Sentiment: Investor materials and transcripts available — full Q1 slide deck and earnings‑call transcript were published for deeper diligence. Earnings Call Transcript Slide Deck
• Neutral Sentiment: Market action reflects the news flow — the stock is trading higher on elevated volume as the market re‑prices growth vs. near‑term profitability concerns.
• Negative Sentiment: EPS missed estimates — reported an EPS loss (reported -$0.25 vs. -$0.20 consensus per MarketBeat / other outlets), underscoring ongoing GAAP losses. MarketBeat Earnings
• Negative Sentiment: Profitability metrics remain weak — negative return on equity and continued GAAP losses mean valuation relies on sustained revenue/CGT momentum. Zacks

Insider Transactions at CryoPort

In other news, insider Mark W. Sawicki sold 3,235 shares of the firm's stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $25,880.00. Following the completion of the transaction, the insider directly owned 103,697 shares in the company, valued at approximately $829,576. This trade represents a 3.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jerrell Shelton sold 7,918 shares of the company's stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $8.00, for a total transaction of $63,344.00. Following the sale, the chief executive officer directly owned 1,054,501 shares in the company, valued at $8,436,008. This trade represents a 0.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 59,939 shares of company stock valued at $471,183. 10.10% of the stock is currently owned by corporate insiders.

Institutional Trading of CryoPort

A number of hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC grew its position in CryoPort by 300.1% in the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company's stock worth $44,000 after acquiring an additional 4,375 shares in the last quarter. Creative Planning purchased a new position in CryoPort in the 2nd quarter worth $96,000. Quadrature Capital Ltd purchased a new position in CryoPort in the 4th quarter worth $97,000. State of Wyoming lifted its stake in CryoPort by 30.2% in the second quarter. State of Wyoming now owns 14,218 shares of the company's stock worth $106,000 after purchasing an additional 3,301 shares during the last quarter. Finally, Corient Private Wealth LLC purchased a new stake in CryoPort during the fourth quarter valued at about $113,000. 92.90% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

CYRX has been the subject of several recent analyst reports. Guggenheim upped their target price on shares of CryoPort from $11.00 to $12.00 and gave the stock a "buy" rating in a research note on Tuesday. Wall Street Zen lowered CryoPort from a "hold" rating to a "sell" rating in a report on Sunday. BTIG Research increased their price target on CryoPort from $15.00 to $17.00 and gave the company a "buy" rating in a research report on Tuesday. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of CryoPort in a research report on Friday, March 27th. Finally, Craig Hallum assumed coverage on CryoPort in a research note on Monday, March 30th. They set a "buy" rating and a $15.00 target price on the stock. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $14.44.

CryoPort Company Profile

CryoPort, Inc NASDAQ: CYRX is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort's product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.